163 related articles for article (PubMed ID: 34432253)
1. Protocols for Synthesis of SNIPERs and the Methods to Evaluate the Anticancer Effects.
Tsukumo Y; Tsuji G; Yokoo H; Shibata N; Ohoka N; Demizu Y; Naito M
Methods Mol Biol; 2021; 2365():331-347. PubMed ID: 34432253
[TBL] [Abstract][Full Text] [Related]
2. Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER).
Ohoka N; Ujikawa O; Shimokawa K; Sameshima T; Shibata N; Hattori T; Nara H; Cho N; Naito M
Chem Pharm Bull (Tokyo); 2019 Mar; 67(3):203-209. PubMed ID: 30369550
[TBL] [Abstract][Full Text] [Related]
3. Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.
Ohoka N; Morita Y; Nagai K; Shimokawa K; Ujikawa O; Fujimori I; Ito M; Hayase Y; Okuhira K; Shibata N; Hattori T; Sameshima T; Sano O; Koyama R; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2018 May; 293(18):6776-6790. PubMed ID: 29545311
[TBL] [Abstract][Full Text] [Related]
4. SNIPERs-Hijacking IAP activity to induce protein degradation.
Naito M; Ohoka N; Shibata N
Drug Discov Today Technol; 2019 Apr; 31():35-42. PubMed ID: 31200857
[TBL] [Abstract][Full Text] [Related]
5.
Ohoka N; Okuhira K; Ito M; Nagai K; Shibata N; Hattori T; Ujikawa O; Shimokawa K; Sano O; Koyama R; Fujita H; Teratani M; Matsumoto H; Imaeda Y; Nara H; Cho N; Naito M
J Biol Chem; 2017 Mar; 292(11):4556-4570. PubMed ID: 28154167
[TBL] [Abstract][Full Text] [Related]
6. Targeted protein degradation and drug discovery.
Naito M
J Biochem; 2022 Jul; 172(2):61-69. PubMed ID: 35468190
[TBL] [Abstract][Full Text] [Related]
7. Specific non-genetic IAP-based protein erasers (SNIPERs) as a potential therapeutic strategy.
Ma Z; Ji Y; Yu Y; Liang D
Eur J Med Chem; 2021 Apr; 216():113247. PubMed ID: 33652355
[TBL] [Abstract][Full Text] [Related]
8. Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs.
Naito M; Ohoka N; Shibata N; Tsukumo Y
Front Chem; 2019; 7():849. PubMed ID: 31921772
[TBL] [Abstract][Full Text] [Related]
9. [Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy].
Ohoka N
Yakugaku Zasshi; 2018; 138(9):1135-1143. PubMed ID: 30175757
[TBL] [Abstract][Full Text] [Related]
10. Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.
Shibata N; Nagai K; Morita Y; Ujikawa O; Ohoka N; Hattori T; Koyama R; Sano O; Imaeda Y; Nara H; Cho N; Naito M
J Med Chem; 2018 Jan; 61(2):543-575. PubMed ID: 28594553
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of SNIPERs against BCR-ABL with kinase inhibitors and a method to evaluate their growth inhibitory activity derived from BCR-ABL degradation.
Cho N; Naito M
Methods Enzymol; 2023; 681():41-60. PubMed ID: 36764763
[TBL] [Abstract][Full Text] [Related]
12. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Shibata N; Miyamoto N; Nagai K; Shimokawa K; Sameshima T; Ohoka N; Hattori T; Imaeda Y; Nara H; Cho N; Naito M
Cancer Sci; 2017 Aug; 108(8):1657-1666. PubMed ID: 28556300
[TBL] [Abstract][Full Text] [Related]
13. Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules.
Okuhira K; Shoda T; Omura R; Ohoka N; Hattori T; Shibata N; Demizu Y; Sugihara R; Ichino A; Kawahara H; Itoh Y; Ishikawa M; Hashimoto Y; Kurihara M; Itoh S; Saito H; Naito M
Mol Pharmacol; 2017 Mar; 91(3):159-166. PubMed ID: 27965304
[TBL] [Abstract][Full Text] [Related]
14. Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs.
Ishikawa M; Tomoshige S; Demizu Y; Naito M
Pharmaceuticals (Basel); 2020 Apr; 13(4):. PubMed ID: 32326273
[TBL] [Abstract][Full Text] [Related]
15. Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy.
Ohoka N; Shibata N; Hattori T; Naito M
Curr Cancer Drug Targets; 2016; 16(2):136-46. PubMed ID: 26560118
[TBL] [Abstract][Full Text] [Related]
16. Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety.
Shoda T; Ohoka N; Tsuji G; Fujisato T; Inoue H; Demizu Y; Naito M; Kurihara M
Pharmaceuticals (Basel); 2020 Feb; 13(3):. PubMed ID: 32106507
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.
Wang C; Zhang Y; Shi L; Yang S; Chang J; Zhong Y; Li Q; Xing D
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1437-1453. PubMed ID: 35589670
[TBL] [Abstract][Full Text] [Related]
18. Development of Chimeric Molecules That Degrade the Estrogen Receptor Using Decoy Oligonucleotide Ligands.
Naganuma M; Ohoka N; Tsuji G; Tsujimura H; Matsuno K; Inoue T; Naito M; Demizu Y
ACS Med Chem Lett; 2022 Jan; 13(1):134-139. PubMed ID: 35059133
[TBL] [Abstract][Full Text] [Related]
19. Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins.
Ohoka N; Tsuji G; Shoda T; Fujisato T; Kurihara M; Demizu Y; Naito M
ACS Chem Biol; 2019 Dec; 14(12):2822-2832. PubMed ID: 31580635
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation.
Shimokawa K; Shibata N; Sameshima T; Miyamoto N; Ujikawa O; Nara H; Ohoka N; Hattori T; Cho N; Naito M
ACS Med Chem Lett; 2017 Oct; 8(10):1042-1047. PubMed ID: 29057048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
